Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends

Published:October 17, 2018DOI:


      • Now evidence for chemo, immuno and targeted therapy in 3rd line treatment OG cancer.
      • Sequential treatment approaches are of benefit to a growing minority of patients.
      • Factors such as PS, prior response and tumour burden may identify potential responders.
      • Refining predictive biomarkers may further aid in effective patient selection.


      There is increasing evidence that treatment beyond second line provides significant survival benefit for selected advanced oesophageal and gastric adenocarcinoma patients, and important randomised controlled trials of both chemotherapy, targeted therapy and immunotherapy have recently been reported in this space. Despite this growing evidence base there are presently no formal guidelines for third line treatment available to clinicians, and as these agents move into routine clinical practice patient selection and rational sequencing of treatment will become an increasingly relevant clinical challenge. This review critically appraises the current evidence base for third line treatment and discusses patient selection, potential predictive biomarkers and future directions for third line treatment in this challenging condition.


      To read this article in full you will need to make a payment


      Subscribe to Cancer Treatment Reviews
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. IARC CancerBase, Int Agency Res Cancer 2014 [accessed 16/12/14].

        • Edgren G.
        • Adami H.-O.
        • Weiderpass E.
        • Nyrén O.
        A global assessment of the oesophageal adenocarcinoma epidemic.
        Gut. 2013; 62 (1406 LP – 1414)
      2. SEER Cancer Statistics Review, 1975-2015.

        • Lee A.
        • Khulusi S.
        • Watson R.
        Which interval is most crucial to presentation and survival in gastroesophageal cancer: a systematic review.
        J Adv Nurs. 2017; 73: 2270-2282
        • Lao-Sirieix P.
        • Fitzgerald R.C.
        Screening for oesophageal cancer.
        Nat Rev Clin Oncol. 2012; 9: 278-287
        • Fitzgerald R.C.
        • di Pietro M.
        • Ragunath K.
        • et al.
        British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus.
        Gut. 2014; 63: 7-42
        • Shaheen N.J.
        • Falk G.W.
        • Iyer P.G.
        • et al.
        ACG clinical guideline: diagnosis and management of Barrett’s Esophagus.
        Am J Gastroenterol. 2016; 111: 30-50
        • Wagner A.D.
        • Unverzagt S.
        • Grothe W.
        • et al.
        Chemotherapy for advanced gastric cancer.
        Cochrane database Syst Rev. 2010; 3: CD004064
        • Lordick F.
        • Mariette C.
        • Haustermans K.
        • et al.
        Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
        Ann Oncol Off J Eur Soc Med Oncol. 2016; 27: v50-v57
        • Smyth E.C.
        • Verheij M.
        • Allum W.
        • et al.
        Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†.
        Ann Oncol. 2016; 27: v38-v49
        • Smyth E.C.
        • Cunningham D.
        Gastric cancer in 2012: defining treatment standards and novel insights into disease biology.
        Nat Rev Clin Oncol. 2013; 10: 73-74
        • Cunningham D.
        • Starling N.
        • Rao S.
        • et al.
        Capecitabine and oxaliplatin for advanced esophagogastric cancer.
        N Engl J Med. 2008; 358: 36-46
        • Okines A.F.
        • Norman A.R.
        • McCloud P.
        • et al.
        Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.
        Ann Oncol. 2009; 20: 1529-1534
        • Guimbaud R.
        • Louvet C.
        • Ries P.
        • et al.
        Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive.
        Féd J Clin Oncol. 2014; 32: 3520-3526
        • Dank M.
        • Zaluski J.
        • Barone C.
        • et al.
        Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.
        Ann Oncol. 2008; 19: 1450-1457
        • Bang Y.J.
        • Van Cutsem E.
        • Feyereislova A.
        • et al.
        Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
        Lancet. 2010; 376: 687-697
        • Hironaka S.
        • Ueda S.
        • Yasui H.
        • et al.
        Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria.
        J Clin Oncol. 2013; 31: 4438-4444
        • Ford H.E.R.
        • Marshall A.
        • Bridgewater J.A.
        • et al.
        Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
        Lancet Oncol. 2014; 15: 78-86
        • Hun Kang J.
        • Il Lee S.
        • Hyoung Lim D.
        • et al.
        Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.
        J Clin Oncol. 2012; 30: 1513-1518
        • Thuss-Patience P.C.
        • Kretzschmar A.
        • Bichev D.
        • et al.
        Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
        Eur J Cancer. 2011; 47: 2306-2314
        • Okines A.F.C.
        • Asghar U.
        • Cunningham D.
        • et al.
        Rechallenge with platinum plus fluoropyrimidine +/- Epirubicin in patients with oesophagogastric cancer.
        Oncology. 2010; 79: 150-158
        • Fuchs C.S.
        • Tomasek J.
        • Yong C.J.
        • et al.
        Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
        Lancet. 2014; 383: 31-39
        • Wilke H.
        • Muro K.
        • Van Cutsem E.
        • et al.
        Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
        LancetOncol. 2014; 15: 1224-1235
        • Davidson M.
        • Chau I.
        Variations in outcome for advanced gastric cancer between Japanese and Western patients: a subgroup analysis of the RAINBOW trial.
        Transl Gastroenterol Hepatol. 2016; 1: 46
        • Koo D.H.
        • Ryu M.-H.
        • Ryoo B.-Y.
        • et al.
        Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution.
        Gastric Cancer. 2015; 18: 346-353
        • Choi I.S.
        • Choi M.
        • Lee J.H.
        • et al.
        Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: a population-based outcomes study.
        PLoS One. 2018; 13: e0198544
        • Davidson M.
        • Cafferkey C.
        • Goode E.F.
        • et al.
        Survival in advanced esophagogastric adenocarcinoma improves with use of multiple lines of therapy: results from an analysis of more than 500 patients.
        Clin Colorectal Cancer. 2018;
        • Fuchs C.
        • Shitara K.
        • Di Bartolomeo M.
        • et al.
        RAINFALL: a randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.
        J Clin Oncol. 2018; 36 (abstr 5)
        • Zhang Z.
        • Chen Z.
        • Zhu X.
        • et al.
        A phase II study of irinotecan as single agent in the third-line treatment of unresectable or metastatic gastric cancer.
        J. Clin. Oncol. 2018; 36 (e16084–e16084): e16084
        • Lee M.J.
        • Hwang I.G.
        • Jang J.S.
        • et al.
        Outcomes of third-line docetaxel-based chemotherapy in advanced gastric cancer who failed previous oxaliplatin-based and irinotecan-based chemotherapies.
        Cancer Res Treat. 2012; 44: 235-241
        • Kang E.J.
        • Im S.A.
        • Oh D.Y.
        • et al.
        Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
        Gastric Cancer. 2013; 16: 581-589
        • Pasquini G.
        • Vasile E.
        • Caparello C.
        • et al.
        Third-line chemotherapy with irinotecan plus 5-fluorouracil in Caucasian metastatic gastric cancer patients.
        Oncology. 2016; 91: 311-316
        • Tabernero J.
        • Shitara K.
        • Dvorkin M.
        • et al.
        LBA-002Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS).
        Ann Oncol. 2018; 29 (mdy208.001–mdy208.001)
        • Shim H.J.
        • Yun J.Y.
        • Hwang J.E.
        • et al.
        Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer.
        Gastric Cancer. 2011; 14: 249-256
        • Ohtsu A.
        • Ajani J.A.
        • Bai Y.-X.
        • et al.
        Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.
        J Clin Oncol. 2013; 31: 3935-3943
        • Al-Batran S.-E.
        • Riera-Knorrenschild J.
        • Pauligk C.
        • et al.
        A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
        J Clin Oncol. 2017; 35: 4
        • Sierra J.R.
        • Tsao M.S.
        c-MET as a potential therapeutic target and biomarker in cancer.
        Ther Adv Med Oncol. 2011; 3: S21-S35
        • Kang Y.K.
        • Muro K.
        • Ryu M.H.
        • et al.
        A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.
        Invest.New Drugs. 2014; 32: 355-361
        • Moehler M.
        • Gepfner-Tuma I.
        • Maderer A.
        • et al.
        Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.
        BMC Cancer. 2016; 16: 699
        • Thuss-Patience P.C.
        • Shah M.A.
        • Ohtsu A.
        • et al.
        Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
        Lancet Oncol. 2017;
        • Makiyama A.
        • Shimokawa M.
        • Kashiwada T.
        • et al.
        Trastuzumab beyond first progression in cases of HER2-positive advanced gastric or gastro-esophageal junction cancer: initial results from KSCC1105, a trastuzumab observational cohort study.
        J Clin Oncol. 2017; 35: 93
        • Palle J.
        • Tougeron D.
        • Pozet A.
        • et al.
        Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.
        Oncotarget. 2017; 8: 101383-101393
        • Pavlakis N.
        • Sjoquist K.M.
        • Martin A.J.
        • et al.
        Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II Trial.
        J Clin Oncol. 2016; 34: 2728-2735
        • Li J.
        • Qin S.
        • Xu J.
        • et al.
        Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction.
        J Clin Oncol. 2016; 34: 1448-1454
        • Maluf-Filho F.
        • Martins B. Da Costa
        • De Lima M.S.
        • et al.
        Etiology, endoscopic management and mortality of upper gastrointestinal bleeding in patients with cancer.
        United Eur Gastroenterol J. 2013; 1: 60-67
        • Cunningham D.
        • Stenning S.P.
        • Smyth E.C.
        • et al.
        Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial.
        Lancet Oncol. 2017; 18: 357-370
        • Tabernero J.
        • Hozak R.R.
        • Yoshino T.
        • et al.
        Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.
        Ann Oncol. 2018; 29: 602-609
        • Kang Y.K.
        • Boku N.
        • Satoh T.
        • et al.
        Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet. 2017; 390: 2461-2471
        • Muro K.
        • Chung H.C.
        • Shankaran V.
        • et al.
        Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.
        Lancet Oncol. 2016; 17: 717-726
        • Fuchs C.S.
        • Doi T.
        • Jang R.W.
        • et al.
        Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical keynote-059 trial.
        JAMA Oncol. 2018; 4
        • Bang Y.-J.
        • Ruiz E.Y.
        • Van Cutsem E.
        • et al.
        Phase 3, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
        Ann Oncol. 2018; (mdy264–mdy264)
        • Shitara K.
        • Özgüroğlu M.
        • Bang Y.-J.
        • et al.
        Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
        Lancet. 2018; 392: 123-133
        • Janjigian Y.Y.
        • Bendell J.
        • Calvo E.
        • et al.
        CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer.
        J Clin Oncol. 2018; 36: 2836-2844
        • Terme M.
        • Colussi O.
        • Marcheteau E.
        • et al.
        Modulation of immunity by antiangiogenic molecules in cancer.
        Clin Dev Immunol. 2012; 2012: 492920
        • Yasuda S.
        • Sho M.
        • Yamato I.
        • et al.
        Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo.
        Clin Exp Immunol. 2013; 172: 500-506
        • Arkenau H.-T.
        • Martin-Liberal J.
        • Calvo E.
        • et al.
        Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF).
        Oncologist. 2018;
        • Catenacci D.V.T.
        • Kim S.S.
        • Gold P.J.
        • et al.
        A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GEJ) junction or gastric (G) cancer.
        J Clin Oncol. 2017; 35 (TPS219–TPS219)
        • Fujiwara Y.
        • Shitara K.
        • Shimizu T.
        • et al.
        Abstract A204: INCB024360 (Epacadostat) monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: primary results from first-in-Japanese phase I study (KEYNOTE-434).
        Mol Cancer Ther. 2018; 17 (A204 LP – A204)
        • Shah M.A.
        • Metges J.-P.
        • Chun P.Y.
        • et al.
        A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.
        J Clin Oncol. 2017; 35 (TPS4141–TPS4141)
        • Taieb J.
        • Moehler M.
        • Boku N.
        • et al.
        Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: current status and future perspectives.
        Cancer Treat Rev. 2018; 66: 104-113
        • Kulangara K.
        • Zhang N.
        • Corigliano E.
        • et al.
        Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer.
        Arch Pathol Lab Med. 2018; (arpa.2018–0043–OA)
        • Bass A.J.
        • Thorsson V.
        • Shmulevich I.
        • et al.
        Comprehensive molecular characterization of gastric adenocarcinoma.
        Nature. 2014; 513: 202-209
        • Middha S.
        • Zhang L.
        • Nafa K.
        • et al.
        Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data.
        JCO Precis Oncol. 2017; 1: 1-17
        • Lin S.J.
        • Gagnon-Bartsch J.A.
        • Tan I.B.
        • et al.
        Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas.
        Gut. 2015; 64: 1721-1731
        • Zheng Y.
        • Zhu X.-Q.
        • Ren X.-G.
        Third-line chemotherapy in advanced gastric cancer: a systematic review and meta-analysis.
        Medicine (Baltimore). 2017; 96: e6884
        • Chan W.
        • Yuen K.
        • Siu S.W.
        • et al.
        Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: a systematic review and meta-analysis.
        Crit Rev Oncol Hematol. 2017; 116: 68-81
        • Aanur P.
        • Gutierrez M.
        • Kelly R.J.
        • et al.
        FRACTION (Fast Real-time Assessment of Combination Therapies in Immuno-Oncology)-gastric cancer (GC): a randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology (IO) agents in patients with advanced GC.
        J Clin Oncol. 2017; 35 (TPS4137–TPS4137)
        • Manji G.A.
        • Bendell J.C.
        • Oh D.-Y.
        • et al.
        MORPHEUS: a phase Ib/II multi-trial platform evaluating the efficacy and safety of cancer immunotherapy (CIT)-based combinations in patients (pts) with gastric or pancreatic cancer.
        J Clin Oncol. 2018; 36 (TPS530–TPS530)